Molnupiravir: A Prodrug of the Ribonucleoside β‐D‐N4‐Hydroxycytidine Triphosphate Inhibits the Propagation of Nervous Necrosis Virus in Grouper Brain Cells

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Chen‐Kung Chi, Vertika Bajpai, Chen‐Hung Li, Hsin‐Yi Tsai, Chien‐Wen Chen, Chao‐An Cheng, Hsia‐Wei Liu, Chi‐Yao Chang
Natura: Artículo Open Access
Pubblicazione: Wiley 2026
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867003383438639104
author Chen‐Kung Chi
Vertika Bajpai
Chen‐Hung Li
Hsin‐Yi Tsai
Chien‐Wen Chen
Chao‐An Cheng
Hsia‐Wei Liu
Chi‐Yao Chang
author_facet Chen‐Kung Chi
Vertika Bajpai
Chen‐Hung Li
Hsin‐Yi Tsai
Chien‐Wen Chen
Chao‐An Cheng
Hsia‐Wei Liu
Chi‐Yao Chang
Chen‐Kung Chi
Vertika Bajpai
Chen‐Hung Li
Hsin‐Yi Tsai
Chien‐Wen Chen
Chao‐An Cheng
Hsia‐Wei Liu
Chi‐Yao Chang
collection Wiley Open Access
contents Molnupiravir: A Prodrug of the Ribonucleoside β‐D‐N4‐Hydroxycytidine Triphosphate Inhibits the Propagation of Nervous Necrosis Virus in Grouper Brain Cells Chen‐Kung Chi Vertika Bajpai Chen‐Hung Li Hsin‐Yi Tsai Chien‐Wen Chen Chao‐An Cheng Hsia‐Wei Liu Chi‐Yao Chang Journal of Fish Diseases ABSTRACT Nervous necrosis virus (NNV) is the causative agent of viral nervous necrosis, otherwise known as viral encephalopathy and retinopathy in larval and juvenile marine fish worldwide. The pandemic outbreaks have caused nearly 100% mortality in hatcheries, leading to significant economic losses in the aquaculture industry. Since NNV attacks the insufficient immune competence fish at early developmental stages, there is an urgent need for effective antiviral drugs. Several nucleoside analogues, including Molnupiravir, have been developed to target viral RNA‐dependent RNA polymerase (RdRp). This study examines the antiviral activity of Molnupiravir against NNV isolated from giant grouper (GG), Epinephelus lanceolatus (Bloch), using grouper brain (GB) cells as an infection model. The inhibition concentration for 50% of maximal effect (EC 50 ) of Molnupiravir on GGNNV propagation in GB cells was determined as 1.87 μM. Surprisingly, the titre of GGNNV reduced 50,000 at 100 μM of Molnupiravir treatment at 4‐day post‐infection, whereas treatment with 200 μM of Molnupiravir resulted in a 10 5 reduction in viral titre. The inhibition of viral replication and translation was further examined using RNA‐fluorescence in situ hybridization (FISH) and immunocytochemistry detection, respectively. Moreover, administration of 100 μM Molnupiravir at early time 0 hpi resulted in a dramatic decrease in viral load, reducing cell‐associated virus by approximately 4000‐fold and released virus by 6000‐fold. Finally, the molecular docking simulation model supports the interaction between NHC‐TP and GGNNV RdRp for the successful therapeutics. These results demonstrated that Molnupiravir is a very effective therapeutic drug for controlling viral nervous necrosis caused by NNV infection. 10.1111/jfd.70121 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1111/jfd.70121
format Artículo Open Access
id wiley_oa_10_1111_jfd_70121
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2026
publisher Wiley
record_format wiley_oa
spellingShingle Molnupiravir: A Prodrug of the Ribonucleoside β‐D‐N4‐Hydroxycytidine Triphosphate Inhibits the Propagation of Nervous Necrosis Virus in Grouper Brain Cells
Chen‐Kung Chi
Vertika Bajpai
Chen‐Hung Li
Hsin‐Yi Tsai
Chien‐Wen Chen
Chao‐An Cheng
Hsia‐Wei Liu
Chi‐Yao Chang
Journal of Fish Diseases
Molnupiravir: A Prodrug of the Ribonucleoside β‐D‐N4‐Hydroxycytidine Triphosphate Inhibits the Propagation of Nervous Necrosis Virus in Grouper Brain Cells Chen‐Kung Chi Vertika Bajpai Chen‐Hung Li Hsin‐Yi Tsai Chien‐Wen Chen Chao‐An Cheng Hsia‐Wei Liu Chi‐Yao Chang Journal of Fish Diseases ABSTRACT Nervous necrosis virus (NNV) is the causative agent of viral nervous necrosis, otherwise known as viral encephalopathy and retinopathy in larval and juvenile marine fish worldwide. The pandemic outbreaks have caused nearly 100% mortality in hatcheries, leading to significant economic losses in the aquaculture industry. Since NNV attacks the insufficient immune competence fish at early developmental stages, there is an urgent need for effective antiviral drugs. Several nucleoside analogues, including Molnupiravir, have been developed to target viral RNA‐dependent RNA polymerase (RdRp). This study examines the antiviral activity of Molnupiravir against NNV isolated from giant grouper (GG), Epinephelus lanceolatus (Bloch), using grouper brain (GB) cells as an infection model. The inhibition concentration for 50% of maximal effect (EC 50 ) of Molnupiravir on GGNNV propagation in GB cells was determined as 1.87 μM. Surprisingly, the titre of GGNNV reduced 50,000 at 100 μM of Molnupiravir treatment at 4‐day post‐infection, whereas treatment with 200 μM of Molnupiravir resulted in a 10 5 reduction in viral titre. The inhibition of viral replication and translation was further examined using RNA‐fluorescence in situ hybridization (FISH) and immunocytochemistry detection, respectively. Moreover, administration of 100 μM Molnupiravir at early time 0 hpi resulted in a dramatic decrease in viral load, reducing cell‐associated virus by approximately 4000‐fold and released virus by 6000‐fold. Finally, the molecular docking simulation model supports the interaction between NHC‐TP and GGNNV RdRp for the successful therapeutics. These results demonstrated that Molnupiravir is a very effective therapeutic drug for controlling viral nervous necrosis caused by NNV infection. 10.1111/jfd.70121 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Molnupiravir: A Prodrug of the Ribonucleoside β‐D‐N4‐Hydroxycytidine Triphosphate Inhibits the Propagation of Nervous Necrosis Virus in Grouper Brain Cells
topic Journal of Fish Diseases
url https://onlinelibrary.wiley.com/doi/10.1111/jfd.70121